Abstract The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential.There are no licensed vaccines to prevent infection and disease.A recombinant Hendra virus soluble G Roper Girth glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial.Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway.Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical.
We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge.Data revealed values of specific binding and neutralizing Face antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.